American Journal of Clinical Dermatology

Article	Citations
Characterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study	142
Prognostic Biomarkers in Evolving Melanoma Immunotherapy	129
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis	124
Frontal Fibrosing Alopecia: An Update	120
Individualized Neoantigen-Directed Melanoma Therapy	92
Blue Nail Discoloration: Literature Review and Diagnostic Algorithms	89
Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease	86
Acknowledgment to Referees	84
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review	78
Chronic Telogen Effluvium: Is it a Distinct Condition? A Systematic Review	75
Tralokinumab for the Treatment of Atopic Dermatitis	70
Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based Study	66
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study”	66
Efinaconazole in Onychomycosis	66
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma	58
Meat Allergy: A Ticking Time Bomb	54
Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments	50
Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases	49
Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma	49
Classification and Treatment of Angioedema without Wheals: A Spanish Delphi Consensus	46
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative	45
Dapsone Use in Dermatology	45
Commentary on “Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology”	45
Rare Autoinflammatory Neutrophilic Dermatoses in Pregnancy: Literature Review	44
Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance	44

Capturing the Diversity of Dermatology—What’s in a Name?	44
Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study	43
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions	42
Comment on “Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial”	41
Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview	39
Economic Burden of Chronic Hand Eczema: A Review	38
Clinical Disease Measures in Generalized Pustular Psoriasis	38
50 Years of Topical Retinoids for Acne: Evolution of Treatment	38
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination	36
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada	35
Hypertrophic Scars and Keloids: Advances in Treatment and Review of Established Therapies	35
Image-Based Artificial Intelligence in Psoriasis Assessment: The Beginning of a New Diagnostic Era?	35
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety	35
The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation	34
Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists	34
Sunscreens and Photoaging: A Review of Current Literature	34
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	34
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics	33
Diagnosis of Generalized Pustular Psoriasis	32
Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments	31
The Potential Role of Cannabidiol in Cosmetic Dermatology: A Literature Review	30
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program	30
What’s New in Topicals for Atopic Dermatitis?	30
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis	29
Non-invasive Skin Imaging in Cutaneous Lymphomas	29
The Current State of Systemic Therapy of Metastatic Uveal Melanoma	28
Clinical Outcomes and Prognostic Factors in Bullous Pemphigoid Patients: A 15-Year Review in China	28
Photoaging: Current Concepts on Molecular Mechanisms, Prevention, and Treatment	27
What’s New in Therapy for Male Androgenetic Alopecia?	27
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)	27
Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What’s New?	26
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study	26
Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendations	25
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials	25
Correction to: Adherence to Hidradenitis Suppurativa Treatment	25
Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020	25
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial	24
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target	24
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History	24
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?	23
Therapeutic Strategies for Untreated Capillary Malformations of the Head and Neck Region: A Systematic Review and Meta-Analyses	23
Correction to: A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions	22
A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results	21
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial	21
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial	20
Pressure and Skin: A Review of Disease Entities Driven or Influenced by Mechanical Pressure	20
Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors	20
Review of Teledermatology: Lessons Learned from the COVID-19 Pandemic	20
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know	20
Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review	20

Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data	20
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments	19
Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment	19
Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis	19
Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clini	19
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice	18
Effect of Vitamin D Serum Levels and Supplementation on Atopic Dermatitis: A Systematic Review and Meta-analysis	18
Eyebrow and Eyelash Alopecia: A Clinical Review	18
Clinical Mimickers Misdiagnosed as Pyoderma Gangrenosum	18
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments	18
The Use of Lasers and Light Devices in Acne Management: An Update	18
Mucocutaneous Manifestations of Recreational Drug Use	17
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study	17
Alopecia Areata: Current Treatments and New Directions	17
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study	17
Characteristics and Burdens of Disease in Patients from Beijing with Generalized Pustular Psoriasis and Palmoplantar Pustulosis: Multicenter Retrospective Cohort Study Using a Regional Database	16
Early Treatment Initiation Improves Outcomes in Nevus of Ota: A 10-Year Retrospective Study	16
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study	16
Targeting Inflammation in Acne: Current Treatments and Future Prospects	16
Comment on: “Eyebrow and Eyelash Alopecia: A Clinical Review”	16
Deucravacitinib for the Treatment of Psoriatic Disease	15
Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study	15
Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database	15
The Role of Diet Modification in Atopic Dermatitis: Navigating the Complexity	15
Muir–Torre Syndrome: A Cutaneous Finding Amidst Broader Malignancies	15
Systemic Versus Topical Corticosteroids in the Treatment of DRESS: A Retrospective Cohort Study Followed by a Meta-Analysis	15
Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study	14
Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program	14
Cutaneous Small Vessel Vasculitis: A Practical Guide to Diagnosis and Management	14
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi	14
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology	14
Eosinophil–Lymphocyte Ratio, Eosinophil–Neutrophil Ratio, and Eosinophil–Monocyte Ratio in Chronic and Severe Urticaria	14
Author’s Reply to Parvathaneni et al. Comment on: “Methotrexate Cutaneous Ulceration: A Systematic Review of Cases”	14
Managing the Patient with Psoriasis and Metabolic Comorbidities	13
Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009–2022)	13
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies	13
Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients	13
Adherence to Hidradenitis Suppurativa Treatment	13
The Busy Arena of Psoriasis Treatments: Improving the Clinician’s Ability to Make the Right Therapeutic Choice	12
Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study	12
Psoriasis Severity and Cardiometabolic Risk Factors in a Representative US National Study	12
Investigational Treatments for Epidermolysis Bullosa	12
Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient	12
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials	12
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies	12
Teledermatology During COVID-19: An Updated Review	12
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program	11
Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis	11
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update	11
Management of Acne in Pregnancy	11
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program	11
Acknowledgement to Referees	11
Approach to the Atypical Wound	11
Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review	11
Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review	11
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis	10
Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea	10
Leukonychia: What Can White Nails Tell Us?	10
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution	10
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?	10
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey	10
Infections in Patients with Atopic Dermatitis and the Influence of Treatment	10
Beyond the Hot Comb: Updates in Epidemiology, Pathogenesis, and Treatment of Central Centrifugal Cicatricial Alopecia from 2011 to 2021	9
Primary Localized Cutaneous Amyloidosis of Keratinocyte Origin: An Update with Emphasis on Atypical Clinical Variants	9
Identifying and Treating Ocular Manifestations in Psoriasis	9
Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review	9
Behçet Disease: An Update for Dermatologists	9
The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis	9
Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options	9
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year	9
Pathophysiology of Generalized Pustular Psoriasis	9
Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management	8
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors	8
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians	8
Photoprotection for Skin of Color	8
From Compression to Itch: Exploring the Link Between Nerve Compression and Neuropathic Pruritus	8
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion	8
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review	8
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy	7
A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris	7

Safety of Hydroxychloroquine: What a Dermatologist Should Know	7
Treat-to-Target in Atopic Dermatitis	7
DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020	7
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis	7
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data	7
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study	7
The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: A Multicenter Prospective Cohort Study	6
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outco	6
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature	6
A Guide to the Management of Hidradenitis Suppurativa in Pregnancy and Lactation	6
Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)	6
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Cl	6
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors	6
The 25th World Congress of Dermatology, Singapore, 3–8 July, 2023: Research Highlights	6
Overcoming Resistance Mechanisms to Melanoma Immunotherapy	6
Acknowledgement to Referees	6
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study	6
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation	6
Pruritus in Pregnancy	6